TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Overexpression of cyclooxygenase 2 (COX-2) is thought to promote survival of transformed cells. Transforming growth factor β (TGF-β) exerts anti-proliferative effects on a broad range of epithelial cells. In the current study, we investigated whether TGF-β can regulate COX-2 expression in A549 human lung adenocarcinoma cells, which are TGF-β-responsive and overexpress COX-2. Materials and Methods Western blotting, Northern blotting, and mRNA stability assays were performed to demonstrate that COX-2 protein and mRNA expression were suppressed by TGF-β. We also evaluated the effects of tristetraprolin (TTP) on COX-2 mRNA using RNA interference. Results We demonstrated that COX-2 mRNA and protein expression were both significantly suppressed by TGF-β. An actinomycin D chase experiment demonstrated that COX-2 mRNA was more rapidly degraded in the presence of TGF-β, suggesting that TGF-β-induced inhibition of COX-2 expression is achieved via decreased mRNA stability. We also found that TGF-β rapidly and transiently induced the expression of TTP, a well-known mRNA destabilizing factor, before suppression of COX-2 mRNA expression was observed. Using RNA interference, we confirmed that increased TTP levels play a pivotal role in the destabilization of COX-2 mRNA by TGF-β. Furthermore, we showed that Smad3 is essential to TTP-dependent down-regulation of COX-2 expression in response to TGF-β. Conclusion The results of this study show that TGF-β down-regulated COX-2 expression via mRNA destabilization mediated by Smad3/TTP in A549 cells.
Abstract
Purpose Overexpression of cyclooxygenase 2 (COX-2) is thought to promote survival of transformed cells. Transforming growth factor β (TGF-β) exerts anti-proliferative effects on a broad range of epithelial cells. In the current study, we investigated whether TGF-β can regulate COX-2 expression in A549 human lung adenocarcinoma cells, which are TGF-β-responsive and overexpress COX-2. Materials and Methods Western blotting, Northern blotting, and mRNA stability assays were performed to demonstrate that COX-2 protein and mRNA expression were suppressed by TGF-β. We also evaluated the effects of tristetraprolin (TTP) on COX-2 mRNA using RNA interference. Results We demonstrated that COX-2 mRNA and protein expression were both significantly suppressed by TGF-β. An actinomycin D chase experiment demonstrated that COX-2 mRNA was more rapidly degraded in the presence of TGF-β, suggesting that TGF-β-induced inhibition of COX-2 expression is achieved via decreased mRNA stability. We also found that TGF-β rapidly and transiently induced the expression of TTP, a well-known mRNA destabilizing factor, before suppression of COX-2 mRNA expression was observed. Using RNA interference, we confirmed that increased TTP levels play a pivotal role in the destabilization of COX-2 mRNA by TGF-β. Furthermore, we showed that Smad3 is essential to TTP-dependent down-regulation of COX-2 expression in response to TGF-β. Conclusion The results of this study show that TGF-β down-regulated COX-2 expression via mRNA destabilization mediated by Smad3/TTP in A549 cells.
참고문헌 (25)
- Gupta RA, "Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2", Nat Rev Cancer, 1, pp.11~21 (2001)
- Setia S, "Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis", Mol Cell Biochem, 366, pp.89~99 (2012)
- Vo BT, "TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K", AKT, Endocrinology, pp.2013, 154[DOI]
- Tian M, "PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis", FASEB J, 24, pp.1105~1116 (2010)
- Heasley LE, "Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer", J Biol Chem, 272, pp.14501~14504 (1997)
- Zhou F, "The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy", PLoS One, 8, pp.e61585~ (2013)
- Ruegg C, "Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics : hypes, hopes and reality", Ann Med, 35, pp.476~487 (2003)
- Dubois RN, "Cyclooxygenase in biology and disease", FASEB J, 12, pp.1063~1073 (1998)
- Massague J, "TGFbeta signaling in growth control, cancer, and heritable disorders", Cell, 103, pp.295~309 (2000)
- 김치홍, "Expression of Transforming Growth Factor β1 and E-Cadherin Proteins in Pulmonary Adenocarcinoma: Its Significance in Tumor Progression", Cancer Research and Treatment, 45(2), pp.118~125 (2013), 대한암학회
- Neil JR, "Cox-2inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms", Carcinogenesis, 29, pp.2227~2235 (2008)
- Chen CY, "AU binding proteins recruit the exosome to degrade ARE-containing mRNAs", Cell, 107, pp.451~464 (2001)
- Sanduja S, "The role of tristetraprolin in cancer and inflammation", Front Biosci(Landmark Ed), 17, pp.174~188 (2012)
- Carballo E, "Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin", Science, 281, pp.1001~1005 (1998)
- Sawaoka H, "Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2mRNA. A polyadenylation variant in a cancer cell line lacks the binding site", J Biol Chem, 278, pp.13928~13935 (2003)
- Sheng H, "Transforming growth factor-beta1 enhances Ha-rasinduced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA", J Biol Chem, 275, pp.6628~6635 (2000)
- Park YG, "Effects of TGFbeta, TNF-alpha, IL-beta and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells", Int J Biochem Cell Biol, 36, pp.2270~2280 (2004)
- Li W, "COX-2silencing inhibits cell proliferation in A549 cell", Chin-Ger J Clin Oncol, 10, pp.423~427 (2011)
- Ogawa K, "Transcriptional regulation of tristetraprolin by transforming growth factor-beta in human T cells", J Biol Chem, 278, pp.30373~30381 (2003)
- Ungefroren H, "Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells : control by Rac1", Mol Cancer, 10, pp.67~ (2011)
- Cha HJ, "Tristetraprolin downregulates the expression of both VEGF and COX-2 in human colon cancer", Hepatogastroenterology, 58, pp.790~795 (2011)
- Tian M, "The TGF-beta paradox in human cancer : an update", Future Oncol, 5, pp.259~271 (2009)
- Kong F, "Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma", Cancer, 86, pp.1712~1719 (1999)
- Connolly EC, "Complexities of TGFbeta targeted cancer therapy", Int J Biol Sci, 8, pp.964~978 (2012)
- Comerci JT Jr, "Induction of transforming growth factor beta-1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene", Clin Cancer Res, 3, pp.157~160 (1997)